An overview of the global peptide therapeutics market, key growth drivers, and emerging trends for industry professionals and investors.
Filed under industry market, written for founder-operator, investor, journalist.
Not medically reviewed. Last updated 2026-05-01. Nothing here is medical advice.
The global peptide therapeutics market has experienced significant growth, driven primarily by GLP-1 receptor agonists, oncology peptides, and increasing investment in peptide drug discovery platforms.
The peptide therapeutics market has been valued at over $40 billion and continues to grow at a double-digit compound annual growth rate. GLP-1-based medications account for a substantial portion of this market.
1. **GLP-1 demand**: Semaglutide and tirzepatide have become blockbuster drugs, driving massive investment in peptide manufacturing capacity.
2. **Oncology**: Peptide-drug conjugates and peptide receptor radionuclide therapy represent growing segments.
3. **Manufacturing innovation**: Advances in solid-phase and liquid-phase synthesis, plus continuous manufacturing, are reducing costs.
4. **Oral peptide delivery**: Technologies enabling oral bioavailability (e.g., oral semaglutide) expand market potential.
5. **Biosimilar peptides**: As patents expire, biosimilar and follow-on peptide products create new market segments.
The regulatory landscape significantly influences market dynamics. FDA actions on compounding, patent litigation, and international regulatory harmonization all affect the competitive landscape.
This article provides industry analysis for educational purposes and does not constitute investment advice.
More guides: All guides, Safety centre, Peptide library.